Are You Eating Too Much Protein? Scientists Finally Weigh In
Rumors have circulated for decades, claiming that too much protein could damage your kidneys, stress your liver, or even weaken your bones. But new research shows there's no solid evidence that high-protein diets are harmful, especially in healthy individuals.
A new study published in The American Journal of Clinical Nutrition found that most of the concerns people have about high-protein diets aren't backed by solid science. To test this, researchers dug through nearly 60 years of data on claims linking high protein intake to issues like kidney damage, liver strain, bone loss, cancer risk, and more. What they found might surprise you."Results from some observational studies have shown associations of high(er) protein intakes with a variety of negative health outcomes," the study authors said. "However, we know of no compelling evidence that, in otherwise healthy humans, there is an upper level of protein intake where the conjectured harms of HP (high-protein) intake have been demonstrated."
According to the new research, many earlier studies have a major flaw: They were conducted on animals, not humans. Others rely on correlation rather than causation, which can skew the results and lead to misleading conclusions.
On the flip side, plenty of research suggests that more protein is generally better. While there's clearly a limit to how much you should eat (though it hasn't been firmly established yet), a study in the Strength and Conditioning Journal found that higher protein intake can support body recomposition, fat loss, and muscle growth. Other research also shows it helps to reduce cravings, lowers blood pressure, and even improves bone density, something especially important as you get older.
Are You Eating Too Much Protein? Scientists Finally Weigh In first appeared on Men's Journal on Jul 17, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year
Moderna (MRNA), once an unknown biotech firm, quickly rose to the top of the global vaccine market during the COVID-19 pandemic. Its mRNA technology platform created one of the world's first and most widely used COVID-19 vaccines. Investors who recognized its potential early saw a dramatic increase in share price, with MRNA stock rising by 1,226.9% between 2020 and 2022. More News from Barchart Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Here's What Happened the Last Time Novo Nordisk Stock Was This Oversold Dear Microsoft Stock Fans, Mark Your Calendars for Aug. 1 Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Now, in this post-pandemic era, vaccine demand is no longer at its peak. The question is whether the company can move beyond its COVID-19 legacy and become a sustainable, diversified biotech company with long-term growth potential. Moderna will report its second-quarter earnings on Aug. 1. The stock is down 22% year-to-date, underperforming the overall market. Let us see if the stock is a buy now on the dip. A Deep and Ambitious Pipeline Valued at $13.1 billion, Moderna is a biotechnology company that develops messenger RNA (mRNA)-based medicines and vaccines. It uses synthetic mRNA to instruct human cells to produce proteins that can aid in disease prevention, treatment, and cure. Its primary areas of focus include infectious diseases, oncology, rare diseases, autoimmune diseases, and cardiovascular diseases. Moderna's revenue increased dramatically during the peak pandemic years, owing primarily to sales of its COVID-19 vaccine, Spikevax. However, as global vaccination rates stabilized, the company's revenue began to decline. Total revenue fell by 35.3% in the first quarter of 2025 to $108 million, owing to lower net product sales. Spikevax sales totaled $84 million, versus $167 million in Q1 2024. This revenue decline has been difficult for investors accustomed to massive pandemic-era revenue. The company's second commercial product is its standalone RSV vaccine, mRESVIA, which received FDA approval in mid-2024 for adults aged 60 and up. It generated $2 million in sales in the first quarter. Moderna is also testing a combined COVID-19/flu vaccine (mRNA-1083), which is currently in phase 3 trials. If approved, this combination has the potential to streamline millions of annual booster shots while also significantly reducing healthcare logistics and costs. Beyond respiratory viruses, Moderna's oncology pipeline is a daring bet on personalized cancer vaccines. Its collaboration with Merck (MRK) has received significant attention, particularly for mRNA-4157, a personalized cancer vaccine for melanoma. Phase 3 trials are currently underway, and if successful, this approach could provide a new edge in immunotherapy. Further down the pipeline are vaccines for rare metabolic diseases like propionic acidemia and methylmalonic acidemia, as well as autoimmune conditions like multiple sclerosis. While these are early stage and speculative, they show the company's desire to become a multi-franchise biotech powerhouse. Despite short-term revenue challenges, Moderna has been aggressively investing in research and development. As of 2025, the company has over 21 mRNA-based programs in development, including Zika, HIV, HSV, Influenza, and Lyme vaccines, among others. R&D spending totalled $856 million in Q1, with a target of $4.1 billion for the year, reflecting the cost of conducting numerous late-stage trials. Moderna's business model is currently losing money due to a dramatic drop in revenue following the pandemic, as well as an increase in expenses. Its net loss stood at $2.52 per share, compared to $3.07 per share in the year-ago quarter. The company expects to return to profitability by 2026, assuming regulatory approvals and successful commercial launches for its next-generation vaccines. However, this may take time. Clinical setbacks, slower-than-expected market adoption, or pricing pressures may all cause a delay in returning to profitability. Nonetheless, Moderna maintains a strong financial position. At the end of the first quarter, the company had more than $8.4 billion in cash and cash equivalents. This strong liquidity position allows for ongoing investment in clinical development, infrastructure expansion, and strategic acquisitions. Analysts expect the company to report a loss of $3 per share in the second quarter, down from $3.33 the previous year. Revenue could fall by 53%, to $112.56 million. Analysts predict $2.07 billion in revenue for the year, which is consistent with management's forecast of $1.5 to $2.5 billion. However, revenue is expected to climb by 16.3% to $2.41 billion in 2026. Moderna has surpassed the earnings consensus four times in the last two years, with six revenue beats. Is Moderna a Buy, Hold, or Sell on Wall Street? The consensus on Moderna stock is an overall 'Hold.' Of the 26 analysts covering the stock, three rate it a 'Strong Buy,' 19 rate it a 'Hold,' one says it is a 'Moderate Sell,' and three rate it a 'Strong Sell.' The average target price of $42.95 implies the stock can rally 30% from current levels. Additionally, its high price estimate of $198 from Brookline Capital Markets suggests upside potential of more than 500% over the next 12 months. While the upside appears unattainable in light of declining vaccine sales, Moderna stock has a track record of delivering outsized gains. A successful clinical trial result or an FDA approval can send a biotech stock skyrocketing. Rebuilding After the Peak Moderna faces the demanding task of reinventing itself for the post-COVID-19 era. This means transitioning from a single-product blockbuster to a diversified innovator with recurring revenues and pipeline-driven growth. Whether the stock has 'legs' in the long run will depend on its ability to introduce new products to the market and expand its reach. It will also have to convince investors that its post-pandemic story is just as interesting as the one that brought it to global prominence in the first place. This risky biotech is a good buy now if you still believe in the company's potential to turn its story around. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
37 minutes ago
- Yahoo
UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy' Rating
Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a 'Buy' rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 sales guidance. The biopharmaceutical company is facing weakness in its diagnostic segment. However, the weakness has not altered UBS's positive stance on the company. That's because the company is experiencing robust growth, with its MedTech division recording 12.2% organic growth in the second quarter, higher than the consensus estimate of 11.2%. In addition, UBS is buoyed by Abbott's 6.9% organic sales growth or 7.5% on excluding COVID diagnostics. The research firm expects robust growth in other segments, including the MedTech pipeline, to offset weakness in the diagnostic segment. Abbott Laboratories (NYSE:ABT) is a global healthcare company focused on creating life-changing technologies and products that span diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It is focused on improving health and well-being across all stages of life through innovative solutions and a commitment to accessibility. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best 52-Week High Stocks to Buy Now and 10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
39 minutes ago
- Washington Post
High Noon recalls vodka seltzers mislabeled as Celsius energy drinks
Popular alcohol brand High Noon issued a voluntary recall of a batch of its variety 12-packs after discovering that some of them contained vodka seltzer mislabeled as Celsius energy drinks. The Food and Drug Administration issued a recall notice Wednesday, warning that the sparkling blue razz flavor of the Astro Vibe energy drink may contain vodka and cause 'unintentional alcohol ingestion.' No illnesses or deaths have resulted so far from the mishap, it said.
